Differential response of psychotic and obsessive symptoms to risperidone in an adolescent

被引:27
作者
DrydenEdwards, RC
Reiss, AL
机构
[1] JOHNS HOPKINS UNIV, SCH MED, DEPT PSYCHIAT, BALTIMORE, MD 21231 USA
[2] JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROL, BALTIMORE, MD 21231 USA
[3] JOHNS HOPKINS UNIV, SCH MED, DEPT PEDIAT, BALTIMORE, MD 21231 USA
关键词
D O I
10.1089/cap.1996.6.139
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
A 13-year-old boy with psychotic, depressive, and obsessive-compulsive symptoms initially presented with auditory and visual hallucinations and a lifetime of excessive worries about contamination. Family history was significant for schizophrenia and compulsive behavior. When treated with clomipramine 100 mg daily (plasma level 85 ng/mL), obsessive-compulsive symptoms but not the hallucinations improved significantly, and racing thoughts and grandiosity developed later. Haloperidol 0.5 mg daily reduced the psychotic symptoms but was poorly tolerated, and then trifluoperazine 3 mg daily was ineffective, so clomipramine was discontinued (without worsening of OCD symptoms). Trifluoperazine in combination with lithium 1500 mg daily (0.9 meq/L), and then with the addition of carbamazepine 250 mg daily (3.7 mu g/mL), was only partially helpful. Dose reductions in any medication led to increased psychotic symptoms within days. Trifluoperazine was then replaced by risperidone 3 mg twice daily. Within 2 weeks of starting risperidone, psychotic symptoms ceased but the patient experienced an incapacitating exacerbation of obsessive-compulsive symptoms, experiencing the most severe symptoms in his illness. Sertraline 50 mg reduced the OCD symptoms only briefly. After 5 months on risperidone, risperidone and sertraline were discontinued, and the obsessive-compulsive symptoms significantly decreased within 2 weeks. These clinical observations suggest that even when risperidone has a therapeutic antipsychotic effect, it may exacerbate obsessive-compulsive symptoms in predisposed adolescents.
引用
收藏
页码:139 / 145
页数:7
相关论文
共 22 条
[1]  
BOWDEN CL, 1995, J CLIN PSYCHIAT, V56, P25
[2]   RISPERIDONE IN ADOLESCENTS [J].
COZZA, SJ ;
EDISON, DL .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1994, 33 (08) :1211-1211
[3]   CLINICAL-EXPERIENCE WITH RISPERIDONE [J].
FRAS, I ;
MAJOR, LF .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1995, 34 (07) :833-833
[4]   CARBAMAZEPINE AS ADJUNCT OR ALTERNATIVE TO LITHIUM IN THE PROPHYLAXIS OF RECURRENT AFFECTIVE-DISORDERS [J].
FRITZE, J ;
BENEKE, M ;
LANCZIK, M ;
SCHNEIDER, B ;
WALDEN, J .
PHARMACOPSYCHIATRY, 1994, 27 (05) :181-185
[5]   THE POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS) FOR SCHIZOPHRENIA [J].
KAY, SR ;
FISZBEIN, A ;
OPLER, LA .
SCHIZOPHRENIA BULLETIN, 1987, 13 (02) :261-276
[6]  
KECK PE, 1995, J CLIN PSYCHIAT, V56, P466
[8]   CAN CLOZAPINE TRIGGER OCD [J].
LEVKOVITCH, Y ;
KRONNENBERG, Y ;
GAONI, B .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1995, 34 (03) :263-263
[9]  
LEYSEN JE, 1994, J CLIN PSYCHIAT, V55, P5
[10]  
MADHUSOODANAN S, 1995, J CLIN PSYCHIAT, V56, P514